 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer...

BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

BioLineRx price target raised to $21 from $19 at H.C. Wainwright

BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates PR Newswire TEL AVIV, Israel, Aug. 30, 2023 - On Track for September 9, 2023 PDUFA Target Action Date...

BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx to Report Second Quarter 2023 Results on August 30, 2023 BioLineRx to Report Second Quarter 2023 Results on August 30, 2023 PR Newswire TEL AVIV, Israel, Aug. 22, 2023 - Management to Hold Conference Call at 10:00 a.m. EDT - TEL AVIV, Israel, Aug. 22, 2023 /PRNewswire/ --BioLineRx Ltd...

BioLineRx to Report Second Quarter 2023 Results on August 30, 2023

StockNews.com began coverage on shares of BioLineRx (NASDAQ:BLRX Free Report) in a research note released on Thursday. The firm issued a sell rating on the biotechnology companys stock. BioLineRx Price Performance Shares of BioLineRx stock opened at $1.37 on Thursday. The company has a quick ratio ...

StockNews.com Initiates Coverage on BioLineRx (NASDAQ:BLRX)

Shares of BioLineRx Ltd. (NASDAQ:BLRX  Get Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.08 and traded as high as...

BioLineRx (NASDAQ:BLRX) Shares Pass Above Two Hundred Day Moving Average of $1.08

BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investigational Candidate Motixafortide BioLineRx Announces Initiation of Randomized Phase 2 Clinical...

BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investigational Candidate Motixafortide

BioLineRx Ltd. (NASDAQ:BLRX  Get Rating)  Analysts at Zacks Small Cap issued their Q2 2023 earnings estimates for shares of BioLineRx in a research report issued on Wednesday, June 7th. Zacks Small Cap analyst J. Vandermosten anticipates that the biotechnology company will post ...

Analysts Offer Predictions for BioLineRx Ltd.'s Q2 2023 Earnings (NASDAQ:BLRX)

BioLineRx Ltd. (NASDAQ:BLRX Get Rating) Investment analysts at Zacks Small Cap issued their Q2 2023 EPS estimates for BioLineRx in a research note issued on Wednesday, June 7th. Zacks Small Cap analyst J. Vandermosten expects that the biotechnology company will post earnings of ($0.01) per share for...

Brokers Set Expectations for BioLineRx Ltd.'s Q2 2023 Earnings (NASDAQ:BLRX)

BioLineRx Ltd. (NASDAQ:BLRX  Get Rating)  Stock analysts at HC Wainwright lowered their Q2 2023 earnings estimates for BioLineRx in a research report issued on Wednesday, May 24th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings of ($0...

HC Wainwright Weighs in on BioLineRx Ltd.'s Q2 2023 Earnings (NASDAQ:BLRX)

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

Watchers	15,116
52-Wk Low	$0.545
52-Wk High	$2.53

Market Cap	$127.39M
Volume (M)	228,536.00
52-Wk High	$2.53
52-Wk Low	$0.545

BLRX BioLineRx, Ltd.

About

Feed

News

Fundamentals